<DOC>
	<DOCNO>NCT02468128</DOCNO>
	<brief_summary>This randomize , double blind , placebo-controlled , single dose study assess safety , efficacy pharmacokinetics intramuscular sebacoyl dinalbuphine ester ( SDE ) post-hemorrhoidectomy pain management .</brief_summary>
	<brief_title>A Study Intramuscular Sebacoyl Dinalbuphine Ester Post-Hemorrhoidectomy Pain Management</brief_title>
	<detailed_description />
	<mesh_term>Nalbuphine</mesh_term>
	<criteria>Male female &gt; = 20 year age Screening Scheduled electively undergo 2 3column excisional hemorrhoidectomy American Society Anesthesiology Physical Class 1 3 Adequate clinical lab value ( value potential clinical concern detail Appendix ) , abnormal , deem clinically significant per Investigator . Ability willingness provide inform consent , adhere study visit schedule complete study assessment language specific questionnaires Body weight less 40 kg . Concurrent fissurectomy . Subject pregnant breastfeeding . Women childbearing potential must negative urine pregnancy test Baseline . Women childbearing potential disagree use acceptable method contraception ( e.g. , hormonal contraceptive , IUD , barrier device abstinence ) throughout study . History hypersensitivity allergy amidetype local anesthetic , opioid , ingredient medication administer study . Subject rest respiratory rate le 8 per minute blood oxygen saturation le 90 mmHg . Use NSAIDs , selective COX2 inhibitor , opioid , acetaminophen , selective serotonin reuptake inhibitor ( SSRI ) , tricyclic antidepressant ( TCA ) , gabapentin , pregabalin within three day surgery . Chronic use opioid medication 14 day last 3 month , nonopioid pain medication 5 time per week screen visit . Use longacting opioid medication within 3 day surgery opioid medication within 24 hour surgery . Current painful physical condition concurrent surgery require analgesic treatment postoperative period . Contraindication epinephrine paincontrol agent plan postoperative use . Administration investigational drug within long 30 day 5 elimination halflives investigational drug prior study drug administration . Any psychiatric disorder , psychological , medical , laboratory condition may interfere study assessment compliance . Significant medical condition laboratory result may indicate increase vulnerability study drug procedure , thus expose subject unreasonable risk result participate clinical trial . Any clinically significant event condition may uncover surgery . History abuse illicit drug , prescription medicine alcohol within past 2 year . Known history antiHIV antibody positive Failure pas drug alcohol screen .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Analgesic</keyword>
	<keyword>Opioids</keyword>
	<keyword>Pain relief surgery</keyword>
	<keyword>Dinalbuphine</keyword>
	<keyword>Sebacoyl Dinalbuphine Ester</keyword>
	<keyword>SDE</keyword>
	<keyword>SDN</keyword>
	<keyword>LT1001</keyword>
</DOC>